GlassScriptPhysician profile
Edward Jose Escobar
NPI 1982685434
$5,559.83
in general payments reported to CMS, 2019-2025
42 companies · $949 in 2025
The $949 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.53 · 2020: $254 · 2021: $563 · 2022: $731 · 2023: $1,653 · 2024: $1,369 · 2025: $949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,971.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,124.32 | 2020-2025 | |
| Abbvie INC. | $1,026.35 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $372.24 | 2020-2024 | Ingrezza, Ongentys |
| Sk Life Science, INC. | $312.33 | 2022-2025 | |
| Argenx US, INC. | $298.39 | 2023-2024 | Vyvgart Hytrulo, Vyvgart |
| Pfizer INC. | $296.34 | 2022-2025 | |
| Ucb, INC. | $258.59 | 2023-2024 | Rystiggo, Fintepla, Nayzilam |
| Neurelis, INC. | $201.61 | 2022-2024 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $147.47 | 2023-2024 | Austedo Xr, Ajovy, Austedo |
| Biohaven Pharmaceuticals, INC. | $136.70 | 2020-2021 | |
| Emd Serono, INC. | $128.69 | 2020-2025 | |
| Avion Pharmaceuticals | $103.71 | 2022-2023 | Dhivy |
| Supernus Pharmaceuticals, INC. | $91.59 | 2022-2025 | Qelbree |
| Medtronic, INC. | $85.15 | 2022-2024 | Intellis Adaptivestim, Closurefast |
| Biogen, INC. | $81.89 | 2020-2024 | Skyclarys |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $69.18 | 2021-2025 | Ocrevus Zunovo, Ocrevus |
| Eisai INC. | $68.53 | 2020-2024 | |
| Lilly USA, LLC | $67.50 | 2024-2025 | Emgality, Amyvid, Kisunla |
| Sumitomo Pharma America, INC. | $65.64 | 2023 | Aptiom |
| Livanova USA, INC. | $64.74 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Allergan, INC. | $63.21 | 2020-2021 | |
| Aucta Pharmaceuticals, INC. | $55.87 | 2024-2025 | Motpoly Xr |
| Impel Pharmaceuticals INC. | $55.48 | 2023 | Trudhesa |
| Otsuka America Pharmaceutical, INC. | $55.42 | 2023-2024 | Rexulti |
| Acadia Pharmaceuticals INC | $40.73 | 2021-2024 | Nuplazid |
| Amneal Pharmaceuticals LLC | $37.45 | 2023-2025 | Crexont, Rytary |
| Grifols USA, LLC | $22.63 | 2023 | Gamunex-C |
| Jazz Pharmaceuticals INC. | $21.47 | 2024 | |
| Alexion Pharmaceuticals, INC. | $20.58 | 2025 | Ultomiris |
| Axsome Therapeutics, INC. | $19.27 | 2025 | Sunosi |
| Cycle Pharmaceuticals INC | $16.61 | 2025 | Ormalvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.62 | 2023 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $15.09 | 2023 | Shingrix |
| Strongbridge US INC. | $14.67 | 2019 | |
| Harmony Biosciences LLC | $14.11 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.97 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.87 | 2023 | Quviviq |
| Upsher-Smith Laboratories LLC | $13.61 | 2021 | |
| Lundbeck LLC | $12.97 | 2020 | |
| Zogenix INC. | $12.60 | 2021 | |
| Vertical Pharmaceuticals, LLC | $11.89 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Escobar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.